Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
EZH2, JMJD3 and UTX have been extensively studied for their involvement in development, immune system, neurodegenerative disease, and cancer.
|
31285428 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Importantly, the Cancer Genome Atlas AML cohort reveals that DOCK5/ 8 levels are correlated with MBD3 and KDM6A, and DOCK5/ 8 expression is significantly increased in patients who are MBD3 low and KDM6A high with a poor survival.
|
30668141 |
2019 |
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
UTX and its protein interactors within the COMPASS family, including the MLL3 and MLL4 lysine methyltransferases, are frequently mutated in multiple human cancers; however, the molecular basis of how these mutations contribute to oncogenesis remains unclear.
|
30753822 |
2019 |
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
KDM6A is mutated in the human condition Kabuki syndrome type 2 (OMIM 300867) and in many cases of cancer.
|
31097364 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
|
31221981 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Likely because its function is contingent on its interacting transcription factors, the effects of UTX inactivation are not uniform and require detailed investigation in each cancer type.
|
30628063 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The X-linked histone demethylase UTX has a pivotal role in cellular and developmental processes including embryogenesis, hematopoiesis and cancer.
|
29421189 |
2018 |
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
KDM6A, an X chromosome-encoded histone demethylase and member of the COMPASS-like complex, is frequently mutated in a broad spectrum of malignancies and contributes to oncogenesis with poorly characterized mechanisms.
|
29533787 |
2018 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Loss or inactivation of the histone H3K27 demethylase UTX occurs in several malignancies, including multiple myeloma (MM).
|
29045832 |
2017 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
A gene co-expression network identified using TCGA prostate tumour RNA-sequencing identifies co-regulated cancer genes associated with 2-oxoglutarate (2-OG) and succinate metabolism, including TET2, lysine demethylase (KDM) KDM6A, BRCA1-associated BAP1, and citric acid cycle enzymes IDH1/2, SDHA/B, and FH.
|
27819678 |
2017 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Despite a high degree of sequence similarity in the catalytic domain between JMJD3 and UTX, numerous studies revealed surprisingly contrasting roles in cellular reprogramming and cancer, particularly leukemia.
|
27151432 |
2016 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We review the most recent evidence on the underlying roles of MLL3/MLL4 and UTX in cancer and highlight key outstanding questions to help drive future research and contribute to our fundamental understanding of cancer and facilitate identification of therapeutic opportunities.
|
27638352 |
2016 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The role and mechanisms of both JMJD3 and UTX have been extensively studied for their involvement in development, cell plasticity, immune system, neurodegenerative disease, and cancer.
|
26193001 |
2015 |
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Cancer genome sequencing has revealed the genetic basis of H3K27me deregulation, including mutations of the components of the H3K27 methyltransferase complex PRC2 and accessory proteins, and deletions and inactivating mutations of the H3K27 demethylase UTX in a wide variety of neoplasms.
|
24987060 |
2014 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We therefore investigated the expression patterns of UTX and JMJD3 in renal cell carcinoma (RCC) and their roles in cancer development.
|
23057811 |
2012 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
A recent large-scale screen of ∼3,500 genes by PCR-based exon re-sequencing identified several new cancer genes in ccRCC including UTX (also known as KDM6A), JARID1C (also known as KDM5C) and SETD2 (ref.2).
|
21248752 |
2011 |
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
After the recent discovery of mutations in KDM6A (UTX), which encodes the histone H3K27me3 demethylase UTX, in several cancer types, EZH2 is the second histone methyltransferase gene found to be mutated in cancer.
|
20081860 |
2010 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
These data identify UTX as a new human cancer gene.
|
19330029 |
2009 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
These data identify UTX as a new human cancer gene.
|
19330029 |
2009 |
Malignant Neoplasms
|
0.600 |
CausalMutation
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.600 |
GenomicAlterations
|
group |
CGI |
|
|
|